Amgen Inc. (NASDAQ:AMGN) is expected to pay $1.00 on Dec 8, 2016. The indicated annual dividend is $4.00. Shareholders owning the stock before Nov 14, 2016 will be eligible to receive the payout. Based on Amgen Inc.’s current price of $149.04, the dividend is 0.67%. This dividend’s record date is Nov 16, 2016 and the announcement date is Oct 17, 2016. The stock decreased 1.67% or $2.53 on November 11, hitting $149.04. About 5.16M shares traded hands or 18.89% up from the average. Amgen, Inc. (NASDAQ:AMGN) has declined 6.03% since April 12, 2016 and is downtrending. It has underperformed by 11.01% the S&P500.
Amgen Inc. is a biotechnology company. The company has a market cap of $109.02 billion. The Firm discovers, develops, makes and delivers various human therapeutics. It has a 14.89 P/E ratio. The Company’s business segment is human therapeutics.
Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.21, from 1.07 in 2016Q1. The ratio is positive, as 56 funds sold all Amgen, Inc. shares owned while 422 reduced positions. 77 funds bought stakes while 533 increased positions. They now own 577.82 million shares or 7.76% less from 626.39 million shares in 2016Q1.
Telemus Capital Lc holds 0.37% or 19,814 shares in its portfolio. Sumitomo Life Ins holds 0.66% or 31,604 shares in its portfolio. Sigma Inv Counselors Incorporated holds 0.12% of its portfolio in Amgen, Inc. (NASDAQ:AMGN) for 4,479 shares. Gemmer Asset Mgmt Lc holds 1,010 shares or 0.08% of its portfolio. The New York-based Gerstein Fisher has invested 0.22% in Amgen, Inc. (NASDAQ:AMGN). The Nebraska-based Nelson Van Denburg And Campbell Wealth Mgmt Grp Inc Limited has invested 0.01% in Amgen, Inc. (NASDAQ:AMGN). Mckinley Management Ltd Company Delaware has 2,303 shares for 0.02% of their US portfolio. Hermes Invest Ltd owns 269,306 shares or 0.82% of their US portfolio. Moreover, Sentinel Asset has 0.95% invested in Amgen, Inc. (NASDAQ:AMGN) for 265,000 shares. Pinebridge Invests L P holds 0.89% or 114,395 shares in its portfolio. Patten Grp Inc, a Tennessee-based fund reported 693 shares. The Alabama-based Stanley has invested 0.24% in Amgen, Inc. (NASDAQ:AMGN). John G Ullman And Assocs accumulated 0.65% or 20,813 shares. Campbell Newman Asset Mgmt holds 2.12% of its portfolio in Amgen, Inc. (NASDAQ:AMGN) for 76,392 shares. Cannell Peter B Co has invested 0.05% of its portfolio in Amgen, Inc. (NASDAQ:AMGN).
Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 1 sale for $523,758 net activity. Shares for $523,758 were sold by Such Annette Louise.
Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage
Out of 17 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 59% are positive. $218 is the highest target while $160 is the lowest. The $187.39 average target is 25.73% above today’s ($149.04) stock price. Amgen Inc. has been the topic of 29 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating by Leerink Swann given on Friday, February 5. Mizuho initiated the shares of AMGN in a report on Tuesday, November 8 with “Buy” rating. The rating was upgraded by Piper Jaffray on Thursday, November 5 to “Overweight”. Vetr upgraded Amgen, Inc. (NASDAQ:AMGN) on Friday, August 21 to “Buy” rating. The firm has “Buy” rating given on Monday, February 8 by Argus Research. The firm has “Market Perform” rating given on Friday, December 4 by Wells Fargo. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Neutral” rating given on Wednesday, September 28 by Citigroup. The stock has “Hold” rating given by Gabelli on Friday, August 26. The stock has “Market Perform” rating given by Bernstein on Wednesday, June 29. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Buy” rating given on Friday, July 31 by Deutsche Bank.
More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Fool.com which released: “Better Buy: Amgen Inc. vs. Johnson & Johnson” on November 08, 2016, also Fool.com with their article: “Why Amgen Inc. Shares Nose-Dived 15.4% in October” published on November 08, 2016, Fool.com published: “5 Things Amgen Inc.’s Management Wants You to Know” on October 28, 2016. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: Prnewswire.com and their article: “Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS …” published on November 10, 2016 as well as Investorplace.com‘s news article titled: “Why McKesson Corporation (MCK), Amgen, Inc. (AMGN) and Electronic Arts Inc …” with publication date: October 28, 2016.
AMGN Company Profile
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.